Capricor Therapeutics(CAPR)
Focus: Capricor Therapeutics is a public biotech focused on cell and exosome-based therapies for rare diseases, primarily in cardiology and muscular dystrophy. The company operates at mid-cap scale with $22M revenue in FY2025 and is publicly traded on NASDAQ (ticker: CAPR).
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
35+8 this month
Growing — net +8 jobs in 30d
23 jobs added vs 15 removed. Steady team buildout.
Should You Work at Capricor Therapeutics?
AI assessmentCapricor offers meaningful scientific opportunity in emerging cell therapies with public company stability, but the stark burn rate and unproven pipeline present material career risk unless you have high risk tolerance for clinical-stage biotech.
Why Work Here
- Leading position in cell therapy for rare disease indications (Duchenne muscular dystrophy, heart failure) with Phase 3 program (Deramiocel) advancing toward potential regulatory catalysts
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$22M
Key Products
Deramiocel
Growing
Growth
Lead program in Phase 3 development; represents company's most advanced asset and primary near-term value driver.
Pipeline & Clinical Trials
Help build intelligence for Capricor Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.